Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mRNA-3745 phase 1/2 study in glycogen storage disease type 1a
NL-OMON59271Phase 2Completed
- Sponsor
- Moderna Inc
- Start
- Sep 2024
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label trial of mRNA-3745 in glycogen storage disease type 1a (GSD1a), sponsored by Moderna Inc. Primary endpoints: Incidence and severity of TEAEs, SAEs, and TEAEs leading to treatment discontinuation and Changes in vital signs, ECG results, and laboratory findings. Started Sep 2024; status: completed.
02
Drugs
mRNA-3745
03
Conditions
glycogen storage disease type 1a (GSD1a)
Beyond the preview
Go deeper on NL-OMON59271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59271.